Skip to main content

Table 2 Molecular characteristics of the tumors

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

   Pt. number %
ER (-) 68 45.0
  (+) 83 55.0
PR (-) 92 60.9
  (+) 59 39.1
bcl-2 (-) 59 39.1
  (+) 92 60.9
p53 0 47 31.1
  1–25% 58 38.4
  26–50% 11 7.3
  51–75% 8 5.3
  76–100% 27 17.9
c-erbB2 0 65 43.0
  + 36 23.8
  ++ 20 13.2
  +++ 30 19.9
Ki-67 < 5% 67 44.4
  ≥5% 84 55.6